Home › Ovarian Cancer › Missouri › Columbia
Ovarian Cancer clinical trials in Columbia, MO
3 studies for Ovarian Cancer are looking for participants at sites in and around Columbia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecruitingPhase 3
- MU Health - University Hospital/Ellis Fischel Cancer Center, Columbia
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- University of Missouri Hospital, Columbia
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RecruitingPhase 3
- Missouri Cancer Associates, Columbia
About Ovarian Cancer
Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.
More about Ovarian Cancer on MedlinePlus
Ovarian Cancer trials in other cities
- Houston, TX90 studies
- New York City, NY75 studies
- Boston, MA62 studies
- Los Angeles, CA53 studies
- Nashville, TN50 studies
- Arlington, VA47 studies
- Philadelphia, PA47 studies
- Columbus, OH39 studies
- St. Louis, MO37 studies
- Chicago, IL36 studies
- San Antonio, TX33 studies
- Pittsburgh, PA32 studies
Other studies in Columbia
- Obesity12 studies
- Cancer (all types)7 studies
- Non-Small Cell Lung Cancer7 studies
- Colorectal Cancer7 studies
- Breast Cancer7 studies
- Type 2 Diabetes6 studies
- Heart Failure5 studies
- Cardiovascular Disease5 studies
- Steatotic Liver Disease5 studies
- Lung Cancer5 studies
- Insomnia4 studies
- Bladder Cancer4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.